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The remodeling of Ca2+ signaling is a common finding in cancer pathophysiology serving the purpose of facilitating proliferation,
migration, or survival of cancer cells subjected to stressful conditions. One particular facet of these adaptive changes is the alteration
of Ca2+ fluxes through the plasma membrane, as described in several studies. In this review, we summarize the current knowledge
about the expression of different Ca2+ channels in the plasma membrane of melanoma cells and its impact on oncogenic Ca2+
signaling. In the last few years, new molecular components of Ca2+ influx pathways have been identified in melanoma cells. In
addition, new links between Ca2+ homeostasis and specific cell processes important in melanoma tumor progression have been
unveiled.Thus, not only do Ca2+ channels appear to have a potential as prognostic markers, but their pharmacological blockade or
gene silencing is hinted as interesting therapeutic approaches.
1. Introduction
Ionized calcium (Ca2+) is a ubiquitous second messenger
that mediates several physiological functions, such as cell
proliferation, survival, apoptosis,migration, and gene expres-
sion. The concentration of Ca2+ in the extracellular milieu
is 1-2mM whereas, at rest, intracellular Ca2+ is maintained
at about 100 nM [1]. Specific Ca2+-transporters and Ca2+-
binding proteins are used by cells to extrude Ca2+ through
the plasma membrane, transport Ca2+ into the intracellular
reservoirs, and buffer cytosolic Ca2+ [2, 3]. Conversely, there
is a diversity of Ca2+ channels in the plasmamembrane allow-
ing Ca2+ entry into the cytosol. Ca2+ influx may cross-talk
with Ca2+ channels present in the endoplasmic reticulum
(ER), resulting in localized Ca2+ elevations that are decoded
through a variety of Ca2+-dependent effectors [1, 4].
It has been long known that external Ca2+ is needed
to induce cell proliferation and cell cycle progression in
mammalian cells [5]. Some studies indicate a requirement
of Ca2+ influx to induce a G1/S-phase during the cell cycle
process [6, 7]. However, in cancer cells such requirement
is modulated by the degree of cellular transformation, so
that neoplastic or transformed cells continue proliferating in
Ca2+-deficient media [8].
Several types of Ca2+ channels have been involved in
cell cycle progression: transient receptor potential melas-
tatin (TRPM), transient receptor potential vanilloid (TRPV),
Transient Receptor Potential Canonical (TRPC), components
of the store-operated calcium entry (SOCE) pathway such as
Ca2+ influx channel (ORAI1) and endoplasmic Ca2+ deple-
tion sensor (STIM1), and voltage-gated calcium channels
(VGCCs) [5]. Through the use of in vitro models, a role
for TRPC1, ORAI1, or STIM1 in Ca2+ signaling changes
associated with the proliferation of endothelial cells has been
uncovered [9, 10]. In addition, L- and T-type VGCCs have
been shown to be upregulated during the S-phase in vascular
smooth muscle cells [11, 12]. T-type channels appear to be
specially suited for promoting cell cycle progression by virtue
of their fast activation uponweak depolarization.This feature
enables transient elevations of cytosolic Ca2+ in nonexcitable
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cells that signal to favor mitotic progression through direct
binding of Ca2+ to intracellular effectors such as calmodulin
(CaM) [4].
Ca2+ influx also plays an important role in tumor growth.
Commonly, cancer cells present alterations of Ca2+ fluxes
across the plasma membrane that reflect changes in the
expression, subcellular localization, and/or function of dif-
ferent types of Ca2+ channels [13, 14]. Among them, the
expression of different members of the TRP family has been
shown to be altered in cancer cells. Particularly, TRPC3 is
induced in breast and ovarian epithelial tumors, and TRPC6
is highly expressed in cancer of breast, liver, stomach, and
esophagus and glioblastoma [14]. Similarly, the expression of
TRPV1 and TRV4 is elevated in human hepatoblastoma and
breast cancer cells, respectively [14, 15], and the expression
level of TRPV6 correlates with tumor progression in prostate,
thyroid, colon, ovarian, and breast cancers [16]. Moreover,
TRPM8 is overexpressed in different carcinomas and has
been proposed to be a “prooncogenic receptor” in prostate
cancer cells [16, 17].
In addition, depletion of Ca2+ from the ER may drive
tumor growth by inducing Ca2+ influx through the plasma
membrane, as the expression of the SOCE canonical com-
ponents STIM1 and ORAI1 is augmented in various cancer
types, including breast cancer, glioblastoma, melanoma, and
esophageal carcinoma (reviewed in [1, 14]).
VGCCs are also involved in cancer progression by gener-
ating oscillatory Ca2+ waves that favor cell cycle progression
[18]. Heightened levels of L-type channel Cav1.2 mRNA
have been reported in colorectal cancer [19]. Several studies
have confirmed the increased expression of T-type Cav3.2
channels in breast, colon, prostate, ovarian, esophageal, and
colon cancers and in glioblastoma, hepatoma, andmelanoma
[20]. However, hypermethylation of the T-type channel gene
CACNA1G (that encodes the Cav3.1 isoform) occurs in
different tumors including colon, pancreatic, and gastric
cancer, suggesting that it acts as a tumor suppressor [21].
Cell physiology aspects other than proliferation are
dependent on Ca2+ influx too. Through cell migration, Ca2+
signaling is involved in the directional sensing of the cells,
in the redistribution and traction force of the cytoskeleton
and in the repositioning of new focal adhesions [22, 23]. Cell
migration is an early prerequisite for tumor metastasis with
enormous impact on patient prognosis [23]. Members of the
same Ca2+ channel families involved in tumor growth have
been implicated in cancer cell migration andmetastasis, such
as TRP channels [24–26], STIM/ORAI-mediated SOCE [27–
30], and T-type VGCCs [31, 32]. For example, TRPM7 has
a promigratory effect on human nasopharyngeal carcinoma
and its expression is related to metastasis formation [24],
being a marker of poor prognosis in human breast cancer
[25]. Nevertheless, TRPM1 expression in mice melanoma
cells is reduced during metastasis [26]. Yang et al. provided
evidence for the role of STIM1 and ORAI1 in the migration
of the breast cancer cells using pharmacological blockers or
siRNA [28]. The significance of STIM1 in focal adhesion and
cell migration is extended to cervical cancer and hepatocellu-
lar carcinoma [29, 30]. Furthermore, it has been shown that
T-type calcium channels regulate cell motility and migration
in fibrosarcoma cells [31]. Conversely, Zhang et al. provided
evidence for T-type channel blockers as dual inhibitors of
proliferation andmigration of human glioblastoma cells [32].
Finally, cell fate is also dependent on Ca2+ influx and
its molecular machinery. Both the pharmacological blockade
and the siRNA-mediated silencing of TRPM8 channels have
been shown to induce the apoptotic death of prostate cancer
cells [33], indicating a critical role for these channels in Ca2+
homeostasis maintenance. It has been suggested that TRPM8
could regulate either proliferation or apoptosis mechanism
in prostate cells, depending on its intracellular localization
[34]. Moreover, TRPV1 has been proposed as a useful target
for killing malignant cells, since mitochondrial function was
inhibited and apoptosis was induced in pancreatic cancer
cells treated with a vanilloid analogue [8, 35]. VGCCs also
play a relevant role in the survival of cancer cells. We
have recently reported that T-type pharmacological blockers
induce apoptosis in melanoma cells, in addition to reducing
its proliferation [36]. Importantly, in the referred work the
pharmacological results were backed up by siRNA-mediated
silencing of Cav3.1 and Cav3.2 T-type channel isoforms.
Likewise, Valerie et al. found that inhibition of T-type
channels by a selective antagonist or siRNA-mediated gene
knockdown not only reduced glioma cell viability but also
induced apoptosis. These effects were reached via inhibition
of the mTORC2/Akt pathway followed by a reduction in the
phosphorylation of antiapoptotic Bad [37].
Hereon, this review will discuss the current knowledge
about the role of different Ca2+ channels expressed in the
plasma membrane of melanoma cells, as well as the Ca2+
signaling pathways involved during tumorigenesis and tumor
progression.
2. Calcium Channels in Melanoma
Cutaneous melanoma is a malignant skin cancer that arises
from transformed melanocytes de novo or from dysplastic,
congenital, or common nevi [50]. Melanoma is the most
dangerous form of skin cancer, and its incidence is steadily
increasing worldwide. In spite of being the subject of intense
laboratory investigations and numerous clinical trials, the
prognosis of metastatic melanoma is still poor. New treat-
ment strategies such as immunotherapy and specific gene
therapy are currently under investigation.
2.1. Transient Receptor Potential Melastatin (TRPM) in
Melanoma. TRP channels are known to regulate melanocyte
physiology, particularly members of the TRPM subfamily
[38]. Untransformed melanocytes express the full-length
TRPM1 mRNA along with an alternative splicing variant
(TRPM1-s) [51]. TRPM1 function appears to be critical to
normal melanocyte pigmentation and melanogenesis, and
thus this channel is a potential target for pigmentation
disorders [52].
TRPM1 was first discovered in B16 mouse melanoma cell
lines as a result of a differential display analysis [26]. This
channel is strongly expressed in poorly metastatic B16 cells
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Figure 1: Ca2+-influx pathways and their physiological functions in melanoma cells. Blue line indicates positive regulation. Red line indicates
inhibition.
and expressed at reduced levels in the highly metastatic B16-
F10 variant [26]. Moreover, in formalin-fixed tissue sections
benign nevi were found to express high levels of TRPM1
that showed a low expression in primarymelanomas whereas
the full-length transcripts were not detected in melanoma
metastases (but several short fragments of TRPM1) [26, 39].
As amatter of fact, several studies point to TRPM1 as a tumor
suppressor in melanoma cells, as its loss of expression corre-
lates with melanocytic tumor progression, metastatic poten-
tial, tumor thickness, and overall melanoma tumor aggres-
siveness (Figure 1; Table 1) [16, 26, 38–41]. In line with this,
it has been suggested that the levels of TRPM1 mRNA can
be used to predict the future development of metastatic
melanoma [16, 38].
The regulation of TRPM1 gene expression has been exten-
sively investigated. It has been proposed that TRPM1 expres-
sion inmelanocytes andmelanoma cells is regulated by a pro-
moter region of the gene that contains four microphthalmia
transcription factor (MITF) binding sites. Several groups
demonstrated that MITF directly regulates the expression of
TRPM1 in vitro and in vivo during melanoma progression
[38, 42, 53, 54].
TRPM1 gene encodes both TRPM1 mRNA and miR-211
which is coded by the sixth intron of the gene. TRPM1 and
miR-211 share the same promoter and are coregulated by
MITF. Similar to TRPM1 protein, miR-211 is highly expressed
in melanocytes and nevi and is reduced in melanoma cells
[55, 56]. Consistently, overexpression of miR-211 exhibited
significant growth inhibition and reduced migration and
invasion in melanoma cells [38, 55–57].
Melanoma cells also express functional TRPM8 channels
that produce a sustainable Ca2+ influx upon activation by
menthol as agonist [43]. Strikingly, in this study the viability
of melanoma cells was dose-dependently depressed in the
presence of menthol, indicating that these channels underlie
tumor progression via the Ca2+ handling pathway and sug-
gesting TRPM8 Ca2+ channels as novel targets of drug devel-
opment for malignant melanoma (Figure 1; Table 1).
Another member of the TRP family, TRPM2, is an ion
channel capable of conferring susceptibility to cell death
upon oxidative stress [58]. Quantitative RT-PCR experiments
revealed that two antisense transcripts (TRPM2-AS and
TRPM2-TE) from the TRPM2 gene were upregulated in
melanoma cells and that their activation was linked to the
hypermethylation of a shared CpG island. Moreover, knock-
down of TRPM2-TE (proposed as a dominant-negative tran-
script) increased the vulnerability of melanoma cells to
undergo apoptosis and necrosis, and overexpression of wild-
type TRPM2 in melanoma cells leads to a faster proliferation
(Figure 1; Table 1) [38, 44].
Finally, TRPM7 receptor has a protective and detoxifying
function in normal andmalignantmelanocytes. In contrast to
TRPM1, TRPM7 is highly expressed in metastatic melanoma
(Figure 1; Table 1) [38, 45].
2.2. Store-Operated Ca2+ Entry (SOCE) in Melanoma. Ca2+
storage in the ER is an essential indicator of the proliferative,
metabolic, and apoptotic status of cells.The retrograde signal-
ing process from ER Ca2+ depletion to SOCE activation has
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Table 1: Expression and physiological role of calcium channels in melanoma.
Ca2+ channel
Expression in
melanoma cells
relative to
melanocytes
Effects References
TRPM1 Verylow/undetectable
Proapoptotic
Reduced metastatic potential
Reduced migration and invasion
[16, 26, 38–42]
TPRM8 Increased Favored tumor progression [17, 43]
TRPM2 Increased Increased proliferation byoverexpression [38, 44]
TRPM7 Increased Favored metastasis and invasion [38, 45]
SOCE Increased ProsurvivalIncreased proliferation [46–48]
T-type Increased
Increased proliferation
Macroautophagy blocked by
pharmacological inhibition/gene
silencing
[36, 49]
a central role in many cellular and physiological functions.
Indeed, SOCE is the main mechanism that implicates Ca2+
import from extracellular to intracellular space, especially in
nonexcitable cells [59]. In the SOCE pathway, STIM proteins
detect the depletion of Ca2+ at the ER and respond by
translocating to the plasma membrane, where they activate
ORAI Ca2+ channels and allow Ca2+ influx.
However, the role of SOCE in melanoma has not been
investigated extensively. One study suggested a functional
relevance for Ca2+-driven growth and survival of melanoma
cells due to the control of SOCE by mitochondria [46].
The authors showed that coupling of mitochondria to SOCE
allows the maintenance of strong Ca2+ fluxes and sustains
a constitutive activation of PKB/Akt pathway, leading to an
increased melanoma cell survival and resistance to apoptosis
(Figure 1; Table 1). The same research group later demon-
strated in vitro and in vivo that lipid rafts are critical for
coupling SOCE to the constitutive activation of PKB/Akt in a
Ca2+/calmodulin-, Src-, and PP2A-mediated pathway. These
results underscore the potential of lipid raft disruptors as
effective anticancer treatments [47].
More recently, Umemura et al. described that prolifera-
tion and migration are also regulated by SOCE in melanoma
cells. They found that STIM1 and ORAI1 were expressed
at high levels in human melanomas and melanoma cell
lines. When SOCE activity was inhibited by pharmacolog-
ical blockade or by siRNA-mediated gene knockdown, the
proliferation rate was halted, cell migration was prevented,
and metastasis progression was delayed (Figure 1; Table 1).
Moreover, their results suggested that melanoma progression
is promoted by SOCE through CaMKII/Raf-1/ERK signaling
pathway, independently of BRAF mutations. Therefore, tar-
geting SOCE could be a new strategy to treat a great number
of melanoma patients, in monotherapy or in combination
with BRAF inhibitors [48].
2.3. Voltage-Gated Ca2+ Channels (VGCCs) in Melanoma.
In 2012, our research group reported that both normal
melanocytes and transformed melanoma cells express func-
tional VGCCs, including members of the Cav1 (L-type),
Cav2 (N, P/Q or R-types), and Cav3 (T-type) families [49].
However, differences were noticed between the different
cell lines regarding the expression of particular isoforms.
Remarkably, untransformedmelanocytes expressed only very
low levels of T-type Cav3.1 channels, whereas transcripts for
T-type Cav3.2 and Cav3.3 channels were undetectable. We
also found a correlation between the proliferation rate and
the expression of specific T-type channels isoforms, such that
the melanoma cell lines displaying a high proliferation rate
expressed higher levels of Cav3.2 channels (Figure 1; Table 1),
whereas those ones growing slowly expressed preferentially
the Cav3.1 isoform. Interestingly, the expression of these two
T-type channel isoforms was counterbalanced. Furthermore,
the results attained in gene knockdown experiments showed
that whereas both Cav3.1 and Cav3.2 isoforms promote the
progression of melanoma cells, the expression of Cav3.1
is associated with slow cycling and it is induced under
hypoxic conditions [49]. In a follow-up study, we described
that clinically used T-type channel pharmacological blockers
induced G1/S cell cycle arrest and also triggered the apoptotic
death of melanoma cells, which was partially dependent on
mitochondrial caspase activation [36]. An in-depth analysis
of the process revealed that apoptosis is preceded by ER stress
and subsequent inhibition of the autophagic flux, which we
found to be constitutively activated inmelanoma cells (Figure
1; Table 1). These effects were mimicked by knockdown of
Cav3.1 and Cav3.2 channels, thus allowing the identification
of these T-type channels as novel targets to deregulate
autophagy and induce cytotoxicity in melanoma cells [36].
3. Conclusions and Future Developments
Recent advances in the understanding of how Ca2+ influx is
involved in melanoma tumorigenesis and progression may
provide new targeted therapies for melanoma treatment.
For this to materialize, it is essential to further deepen the
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study of the role of plasma membrane Ca2+ channels in
melanoma cell proliferation and also in other less explored
areas, such as migration or survival. In light of current
knowledge, the selective activation of certain TRP channel
isoforms and/or the development of humanized inhibitory
antibodies to extracellular domains of TRP channels arise as
putative therapeutic strategies [15, 16, 51]. Also, the blockade
of Ca2+ influx through the use of pharmacological SOCE
blockers and/or raft-targeting agents appears as an interesting
approach to tackle melanoma progression [47, 48]. Finally,
we highlight the potential of T-type Ca2+ channels as novel
prognosis markers and/or therapeutic targets in melanoma.
In this regard, our studies have uncovered a dual role of T-
typeCa2+ channels in controllingmelanoma cell proliferation
and Ca2+ homeostasis, with an impact on adaptive cancer
cell mechanisms like ER stress and macroautophagy that are
often associated with chemotherapeutic or radiotherapeutic
resistance [36, 49]. Thus, existing Ca2+ channel blockers may
expand the pharmacological arsenal and become valuable
partners for combined chemotherapies against melanoma.
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